Targeted Therapies for Soft Tissue Sarcomas

George D. Demetri, MD


July 07, 2023

Gastrointestinal stromal tumors (GIST) were the first type of soft tissue sarcoma (STS) to be treated with the targeted tyrosine kinase inhibitor (TKI) imatinib. Since those dramatic results were revealed, many second- and third-generation TKIs have been shown to be active in GIST, and other targeted therapies have been used for numerous types of STS.

Across this field of rare, heterogeneous malignancies, Dr George Demetri, from Dana-Farber Cancer Institute in Boston, tracks the expanding number of targeted therapies for STS, including neurotrophic tyrosine receptor kinase (NTRK) fusion inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and a variety of more recent inhibitors that have changed the landscape and significantly improved outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.